Zhejiang East Asia Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical chemicals, active pharmaceutical ingredients (APIs), intermediates, tablets, granules, and capsules. Its core products include quinolones synthetic antibacterial agents such as ofloxacin and levofloxacin; antifungal drugs including ketoconazole and tioconazole; gastrointestinal medications; semi-synthetic cephalosporin antibiotics and intermediates like cefaclor, cefdinir, cefixime, cefmetazole sodium, and cefotetan disodium; carbapenem antibiotics such as faropenem; antiviral agents; central nervous system medications including donepezil hydrochloride; respiratory drugs; antiallergic agents; antineoplastic agents and tumor adjuvant drugs. The company also provides treatments for cardiovascular, anti-aging dementia, digestive system, diabetic neuropathy, and anti-pathogenic microorganisms. It operates primarily in China but serves customers across Europe, the United States, Southeast Asia, and internationally through an extensive sales network. Founded in 1992 and headquartered in Taizhou City, Zhejiang Province, China, Zhejiang East Asia Pharmaceutical employs over 1,000 personnel and holds various certifications including CGMP, European Union EDQM, and Japan PMDA. Recent years have seen the company enhance its production capabilities and customize product offerings through its own R&D team and production lines, maintaining a strategic focus on quality and cost efficiency. It has also strengthened its position as a national high-tech enterprise and secured long-term cooperative relationships globally, reflecting its business expansion and operational enhancements within the last two years.